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Aims Angiogenic factors play an important role in the development of atherosclerosis and show pronounced changes
during acute myocardial infarction (AMI). We analysed the impact of placental growth factor (PlGF) and its
endogen opponent, soluble fms-like tyrosine kinase-1 (sFlt-1), on clinical outcome and the early diagnosis of AMI.
Methods
and results
This multicentre study enrolled patients presenting with symptoms suggestive of AMI. The final diagnosis was adju-
dicated by two independent physicians. Levels of sFlt-1 and PlGF were compared with results of a standard troponin
T and a novel high-sensitive troponin (hsTnT) assay. Of the 763 patients enrolled, 132 were diagnosed with AMI.
Multivariable Cox regression analysis demonstrated sFlt-1 .84 ng/L [hazard ratios (HR) 2.6, 95% confidence
intervals (CI) 1.2–5.4, P ¼ 0.01] and PlGF .20 ng/L (HR 3.6, 95% CI 1.3–10.4, P ¼ 0.02) as predictors for mortality
during 1-year follow-up, independent from information provided by troponin T and N-terminal pro-B-type natriuretic
peptide (NT-proBNP). However, only sFlt-1 persisted as independent predictor for mortality when analysed
together with hsTnT and NT-proBNP, and after adjusting for significant clinical parameters. For the diagnosis of
AMI, the combination of troponin T and sFlt-1 improved the performance of troponin T alone and led to a negative
predictive value of 98.3% already at time of presentation. However, sFlt-1 and PlGF added only limited diagnostic
information when used together with hsTnT.
Conclusion Only sFlt-1 but not PlGF provides overall independent prognostic information in patients presenting with symptoms
suggestive of AMI. After the introduction of hsTnT in clinical routine, sFlt-1 and PlGF can only add limited diagnostic
information for the detection or exclusion of AMI. Clinical Trial Registration Information: ClinicalTrials.gov,
NCT00470587
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Introduction
Symptoms suggestive of an acute myocardial infarction (AMI) are
among of the most common reasons why patients are seen at an
emergency department (ED).1 Today, cardiac troponin is one of
the major cornerstones for risk stratification and diagnosis of
patients in this setting due to its high specificity for myocardial
injury, its high clinical sensitivity and also because it provides
important prognostic information.1– 3 However, major limitations
of cardiac troponin are its low sensitivity for detection of AMI
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within the first hours after onset of symptoms,1,4 and its limited
coverage of all prognostic aspects as demonstrated by comparison
with other biomarkers.5– 7 As a consequence, optimal risk stratifi-
cation of a large proportion of patients with suspected AMI at time
of presentation is difficult, leading to extensive monitoring until
AMI can be excluded.8,9 Furthermore, 1–2% of patients who
have an AMI are misdiagnosed and sent home leading to adverse
outcomes.5 Therefore, the need for biomarkers for risk stratifica-
tion and rapid diagnosis in patients with suspected AMI is an
ongoing issue.
Recent investigations have given detailed insights into pathophy-
siology of atherosclerosis and led to the development of novel
cardiac biomarkers.5,10 Angiogenic factors are some promising can-
didates since recent data imply that they are not only important in
the development and progression of atherosclerosis, but also seem
to be involved in the pathogenesis of AMI.11–17 The vascular endo-
thelial growth factor receptor-1, also called fms-like tyrosine
kinase-1 (Flt-1), is expressed on endothelial cells and macro-
phages.17 It binds not only vascular endothelial growth factor but
also placental growth factor (PlGF), a platelet-derived protein, of
which the biological functions are incompletely understood. Pla-
cental growth factor appears to promote the inflammatory
process of atherosclerosis, which includes the recruitment of cir-
culating macrophages and atherosclerotic intimal thickening.15,16
In patients with acute coronary syndrome, PlGF is increased
regardless of the cardiac troponin concentration, which implies
that it is a biomarker of ischaemic events such as plaque instability,
plaque disruption, or impending thrombosis.5,13 A potential
endogenous opponent of PlGF is soluble Flt-1 (sFlt-1), which rep-
resents a type of Flt-1 without the transmembrane and intracellular
tyrosine kinase domain.12,17 It is thought to be able to capture PlGF
and to reduce thereby the amount available to bind to the recep-
tor located on macrophages and endothelial cells.17 An increase of
progenitor cells expressing Flt-1 was described in patients with
AMI,18 suggesting a potential early repair mechanism associated
with angiogenic signalling. As both sFlt-1 and PlGF, have also
demonstrated changing blood levels during ongoing AMI,11,14
they might be useful biomarkers for acute as well as long-term
risk stratification.
Therefore, we analysed the prognostic and diagnostic impact of
sFlt-1 and PlGF in a large cohort of patients presenting to the
ED with symptoms suggestive of AMI as single markers as well
as in addition to a contemporary cardiac troponin and a novel high-
sensitive troponin (hsTnT) assay.
Methods
Study design and population
The Advantageous Predictors of Acute Coronary Syndrome Evaluation
(APACE) trial is an ongoing prospective, observational multicentre study
designed and co-ordinated by the University Hospital Basel. Patients
presenting to the ED with symptoms suggestive of cardiac ischaemia
at rest or minor exertion within the last 12 h were enrolled.
Patients had to be at least 18 years old and have given written
informed consent. Patients with a positive troponin test prior to pres-
entation, cardiogenic shock, terminal kidney failure requiring dialysis, or
anaemia requiring transfusion were excluded. The study was carried
out according to the principles of the Declaration of Helsinki and
approved by the local Ethics Committees.
Clinical and laboratory procedures
All patients underwent an initial clinical assessment including clinical
history, physical examination, 12-lead electrocardiogram (ECG), con-
tinuous ECG-monitoring, pulse oximetry, and standard blood tests
including the local cardiac troponin assay. Evaluation and treatment
of patients were left to the discretion of the attending physicians and
were performed according to standard practice of the hospital and
current guidelines.
Blood samples for determination of investigational biomarkers
were collected at presentation to the ED into serum tubes and
before start of therapy with heparin. Within 1 h, samples were care-
fully processed to avoid changes in marker levels (e.g. by cell
activation) and frozen at 2808C until assayed in a blinded fashion
in two batches in a dedicated core laboratory. Troponin T was deter-
mined using a one-step enzyme immunoassay based on electrochemi-
luminescence technology (Roche Diagnostics, Germany), with a lower
limit of detection of 0.01 mg/L. sFlt-1, PlGF, and hsTnT were
measured with precommercial sandwich enzyme electrochemilumi-
nescence immunoassays (Roche Diagnostics, Germany). The limit of
detection for sFlt-1 was 10 ng/L with a maximum detectable value
of 85 000 ng/L. The intra-assay coefficient of variation was 1.6%
(63 ng/L) and 0.8% (589 ng/L), and the inter-assay coefficient of
variation 4.3% (63 ng/L) and 2.3% (589 ng/L). For PlGF, the limit of
detection was 3 pg/mL with a maximum detectable value of
10 000 ng/L. The intra-assay coefficient of variation was 1.1%
(107 ng/L) and 1.2% (563 ng/L), and the inter-assay coefficient of
variation 2.7% (107 ng/L) and 2.6% (563 ng/L; preliminary results pro-
vided by Research and Development of Roche Diagnostics,
Germany). High-sensitive troponin T had a limit of detection of
0.002 mg/L, a 99th-percentile cut-off point of 0.014 mg/L, and a coef-
ficient of variation of ,10% at 0.013 mg/L.
Adjudicated final diagnosis and follow-up
The final diagnosis was independently adjudicated by two blinded phys-
icians as previously described.19,20 In brief, the physicians had access to
all available medical records and data (including local cardiac troponin
values, ECG, echocardiography, cardiac exercise testing, and coronary
angiography) but were blinded to the results of investigational bio-
markers. Acute myocardial infarction was defined as recommended
in current guidelines and described previously.20 Unstable angina was
diagnosed when a patient had normal troponin levels and typical
angina at rest, a deterioration of previously stable angina, a positive
result on a cardiac exercise test or cardiac catheterization showing
coronary arteries with stenosis of 70% or more of the vessel diameter,
or when the diagnosis was uncertain but follow-up information
showed that the patient had an AMI or a sudden, unexpected
cardiac death within 60 days after presentation.
To obtain a 12-month follow-up, all patients were contacted by
phone after 6 and 12 months. For patients reporting cardiac symptoms,
at least one ECG and clinical examination were performed at the out-
patient clinic or by the referring physician. All information of sub-
sequent hospital admissions or provided by the referring physician
or outpatient clinic were adjucated by independent physicians and
entered into the computer database.
Statistical analysis
This manuscript represents an exploratory analysis based on the data
set of the APACE study. Due to the extreme skewness of markers, we
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used cut-offs for 1-year mortality determined by a classification and
regression trees (CART) model. To summarise differences in
outcome between different biomarkers, we derived hazard ratios
(HR) with associated 95% confidence intervals (CI) from the Cox pro-
portional hazards model. All variables predictive for mortality in uni-
variable analysis (P, 0.05) were included in our multivariable models.
We assessed the sensitivity and specificity of different biomarkers
for the diagnosis of AMI by receiver operating characteristic (ROC)
analysis. Logistic regression analysis was used to combine troponin T
with novel markers. Receiver operating characteristic curves were
compared using the method described by DeLong. To determine
the place value and best cut-off of the novel biomarkers, we performed
CART analyses for the diagnosis of AMI (CHAID algorithm, P-value
adjustment by Bonferroni method). As a first step, we entered all avail-
able biomarkers as continuous variables in our model. As a second
step, we added all available baseline characteristics (Table 1).
If not stated otherwise, continuous Gaussian variables are reported
as mean+ standard deviation and compared by one-way ANOVA.
Non-Gaussian variables identified by Komolgorov–Smirnov test
were described as median (inter-quartile range) and tested by the
Mann–Whitney U test for two groups or the Kruskal–Wallis H test
for more than two groups. Discrete variables are reported as counts
(percentages), and we tested differences between groups with the
x2 test or Fisher exact test when expected cell sizes were ,5. In
the two-sided test, a P-value of ,0.05 was regarded as significant. Stat-
istical analyses were performed using SPSS version 18.0 (SPSS Inc,
Chicago, IL, USA).
Results
From April 2006 to April 2008, we enrolled 794 patients, 8
patients were excluded due to missing blood samples. From the
remaining patients, results from troponin T and sFlt-1 testing at
presentation were available in 763 patients. Baseline characteristics
of this cohort are presented in Table 1. The mean age in our popu-
lation was 63 years, and 93% had at least one and 66% at least two
cardiovascular risk factors. Acute myocardial infarction was diag-
nosed in 132 (17%) patients; the proportion of ST-elevation AMI
was 30%. Unstable angina was the final diagnosis in 119 (16%) indi-
viduals. In the remaining 512 patients without AMI or unstable
angina, the most common diagnoses were musculoskeletal and
pleural pain as well as mental disorders.
Individuals with the diagnosis of AMI were significantly older, dis-
played a higher proportion of arterial hypertension, history of a
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Table 1 Baseline characteristics
Whole cohort (n 5 763) AMI (n 5 132) No AMI (n5 631) P-value
Age (years) 63 (50–75) 72 (59–80) 61 (49–74) ,0.001
Male sex 501 (66) 93 (71) 408 (65) 0.20
Cardiovascular risk factors
Arterial hypertension 462 (61) 94 (71) 368 (58) 0.006
Hyperlipidaemia 330 (43) 66 (50) 264 (42) 0.09
Diabetes mellitus 123 (16) 27 (21) 86 (15) 0.14
Current smoking 187 (25) 38 (29) 149 (24) 0.21
Body mass index (kg/m2) 26 (24–29) 26 (24–29) 26 (24–29) 0.90
Known coronary artery disease 264 (35) 46 (35) 218 (35) 0.95
Previous myocardial infarction 193 (25) 35 (27) 158 (25) 0.72
Previous revascularization 213 (28) 31 (24) 182 (29) 0.21
Known peripheral artery disease 48 (6) 13 (10) 35 (6) 0.06
Previous stroke 47 (6) 15 (11) 32 (5) 0.006
Impaired renal function (GFRa ,60 mL/min) 94 (12) 31 (24) 63 (10) ,0.001
Medication at presentation
Aspirin 292 (38) 53 (40) 239 (38) 0.63
Thienopyridine 79 (10) 8 (6) 71 (11) 0.08
Beta-blocker 299 (39) 50 (38) 249 (40) 0.74
ACE inhibitor and/or ARB 303 (40) 57 (43) 246 (39) 0.37
Nitrate 88 (12) 19 (14) 69 (11) 0.26
Statin 262 (34) 43 (33) 219 (35) 0.64
ECG at presentation
Left bundle branch block 27 (4) 12 (9) 15 (2) ,0.001
ST-segment elevation 54 (7) 38 (29) 16 (3) ,0.001
ST-segment depression 74 (10) 27 (21) 47 (7) ,0.001
T-wave inversion 52 (7) 19 (14) 33 (5) ,0.001
Data are expressed as median (inter-quartile range) or number of patients (percentage) and compared by Mann–Whitney U or x2 test.
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker.
aGlomerular filtration rate (calculated using the MDRD formula).
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previous stroke, and impaired renal function, and had more often
ischaemic changes on ECG. Levels of biomarkers were significantly
higher in patients with AMI (Table 2), and levels of sFlt-1 and PlGF
showed significant differences according to diagnosis (Figure 1).
One-year follow-up was completed in 99.2% of patients. The com-
posite endpoint of death or non-fatal AMI was recorded in 73
patients (9.6%; 41 deaths and 41 AMI). While levels of troponin
T and hsTnT showed an excellent correlation (r2¼ 0.99; P,
0.001), levels of sFlt-1 (r2¼ 0.02; P, 0.001), and PlGF (r2¼ 0.03;
P, 0.001) demonstrated only a weak correlation with troponin T.
Prognostic impact of soluble fms-like
tyrosine kinase-1 and placental growth
factor
Kaplan–Meier analysis according to cut-off of sFlt-1 (85 ng/L)
determined by CART analysis demonstrated a low 1-year mortality
in patients with sFlt-1 ≤85 ng/L of 2.5% compared with 11.9% in
patients with a sFlt-1 level above the cut-off (P, 0.001). Accord-
ing to levels of PlGF at presentation (≤20 and .20 ng/L), the
1-year mortality was 1.5 and 7.4% (P, 0.001). Further Kaplan–
Meier analyses using strata defined by cut-offs of N-terminal
pro-B-type natriuretic peptide (NT-proBNP), troponin T, and
hsTnT derived from CART analysis together with sFlt-1 and
PlGF showed that both markers extend significantly the prognostic
information of the other markers (Figure 2). Univariable Cox
regression analysis confirmed sFlt-1 .85 ng/L (HR 5.3, 95% CI
2.7–10.2, P, 0.001) as well as PlGF (HR 7.6, 95% CI 2.7–21.6,
P, 0.001) as predictors of mortality. In a multivariable analysis
together with NT-proBNP .174 ng/L (HR 14.6, 95% CI 1.9–
112.0, P ¼ 0.01) and troponin T .0.01 mg/L (HR 1.5, 95% CI
0.7–3.0, P ¼ 0.29), both markers demonstrated an independent
prognostic value. The corresponding HR for sFlt-1 was 2.6 (95%
CI 1.2–5.4, P ¼ 0.01) and for PlGF 3.6 (95% CI 1.3–10.4, P ¼
0.02). Repeating the same analysis with hsTnT instead of troponin
showed that only sFlt-1 (HR 2.6, 95% CI 1.3–5.00, P ¼ 0.006) but
not PlGF (HR 2.5, 95% CI 0.9–7.1, P ¼ 0.08) persisted as an inde-
pendent predictor for mortality. In a multivariable analysis together
with all baseline characteristics predictive in univariable analysis for
mortality, only sFlt-1 persisted as an independent predictor
(Table 3). Similar findings were obtained for Kaplan–Meier and
Cox analyses for mortality and non-fatal AMI (data not shown).
Diagnostic impact of soluble fms-like
tyrosine kinase-1 and placental growth
factor
Receiver operating characteristic analysis demonstrated that tropo-
nin T and hsTnT had with an area under the curve (AUC) of 0.88
(95% CI 0.83–0.93) and 0.96 (95% CI 0.95–0.98), respectively, the
best diagnostic performance regarding the diagnosis of AMI
(Figure 3A). The AUC of sFlt-1 and PlGF was 0.70 (95% CI 0.64–
Figure 1 Levels of soluble fms-like tyrosine kinase-1 and placental growth factor according to final diagnosis. STEMI, ST-elevation myocardial
infarction; NSTEMI, non-ST-elevation myocardial infarction; UA, unstable angina; ACS, acute coronary syndrome. Box plots with Tukey whis-
kers; horizontal bars indicate median; extremes of boxes show 25 and 75% confidence interval. Comparison between groups by Kruskal–Wallis
test.
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Table 2 Investigational biomarkers at presentation
Whole cohort (n5 763) AMI (n5 132) No AMI (n5 631) P-value
Troponin T (mg/L) 0.01 (0.01–0.01) 0.09 (0.03–0.33) 0.01 (0.01–0.01) ,0.001
High-sensitive troponin T (mg/L) 0.008 (0.004–0.021) 0.116 (0.049–0.344) 0.006 (0.003–0.012) ,0.001
Creatinine kinase (U/L) 102 (72–154) 145 (96–240) 98 (70–136) ,0.001
Myoglobin (mg/L) 43 (31–64) 90 (54–228) 39 (30–55) ,0.001
NT-proBNP (ng/L) 175 (53–605) 890 (291–3315) 135 (43–376) ,0.001
Soluble fms-like tyrosine kinase-1 (ng/L) 72 (62–91) 90 (70–134) 70 (61–84) ,0.001
Placental growth factor (ng/L) 20 (16–25) 22 (19–27) 20 (16–24) 0.002
Data are expressed as median (inter-quartile range) and compared by Mann–Whitney U test.
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0.76) and 0.60 (95% CI 0.54–0.66), respectively. The combination
of troponin T and sFlt-1 achieved, with an AUC of 0.93 (95% CI
0.90–0.96), a considerably higher diagnostic performance than tro-
ponin T alone (P ¼ 0.04; Figure 3B). The highest difference
compared with troponin T alone was found in patients presenting
within 2 h after onset of symptoms (AUC 0.85 vs. 0.71;
P ¼ 0.03) but the dual-marker strategy was also associated with
a numerical higher AUC compared with the single-marker strategy
Figure 2 Mortality within 12-month follow-up. In the subgroup of troponin T ≤0.01 mg/L, P-value (by log-rank test) for comparison of
soluble fms-like tyrosine kinase-1 strata was 0.03 and for placental growth factor strata 0.01. No significant difference in soluble fms-like tyrosine
kinase-1 strata and placental growth factor strata in the subgroups of high-sensitive troponin T and N-terminal pro-B-type natriuretic peptide
below cut-off. P-value was in all subgroups of N-terminal pro-B-type natriuretic peptide, troponin T, and high-sensitive troponin T above cut-off
,0.001.
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in all strata of time (Figure 4). However, the AUC for hsTnT
exceeded always the results of the combination of troponin T
and sFlt-1, and also the combination of hsTnT with sFlt-1 did
not further improve this result [AUC 0.96 (95% CI 0.95–0.98);
Table 4].
To better assess the utility for clinical application of these novel
biomarkers, we performed CART analyses to determine their
place value and best cut-off. As a first step, we entered all available
biomarkers in our model (Figure 5A). Troponin T with a cut-off of
0.01 mg/L was the best discriminator between patients with or
without AMI. In patients with troponin T ≤0.01 mg/L sFlt-1
emerged as second-best predictor for AMI. Patients with an
sFlt-1 level above 104 ng/L had an AMI 8.7 times more often com-
pared with those below that cut-off. The negative predictive value
of an sFlt-1 level ≤104 ng/L combined with a troponin T level
≤0.01 mg/L for ruling out of AMI with one single blood test at
presentation was 98.3% (Table 4). With this approach, AMI could
have been ruled out already at time of presentation in 509
(81%) of the 631 patients without the final diagnosis of AMI. In
patients with troponin T .0.01 mg/L, a PlGF level below 22 ng/L
increased the proportion of patients diagnosed with AMI to 91%
compared with 73% with troponin T .0.01 mg/L alone. After
entering all baseline variables into the model, we found a similar
distribution (Figure 5B). However, as second-best discriminator
between patients with or without AMI emerged the presence of
ST-segment elevations both in patients with troponin T above
and below the cut-off of 0.01 mg/L. Together with an sFlt-1 level
≤104 ng/L and a troponin T level ≤0.01 mg/L, patients without
ST-segment elevations had a negative predictive value for AMI of
99%.
The CART analysis with hsTnT showed that sFlt-1 and PlGF can
add some diagnostic information (Figure 6A). While hsTnT levels
≤0.011 mg/L excluded an AMI by 99%, levels between .0.011
and 0.031 mg/L that represent the area around the cut-off for diag-
nosis of AMI could be more precisely specified with the use of
sFlt-1. These findings consisted also in the CART analysis including
all baseline variables (Figure 6B).
Since ST-segment elevations turned out to be the second-best
discriminator for AMI, we performed a subgroup analysis excluding
patients with ST-elevation AMI to test if the diagnostic perform-
ance of the novel biomarkers stays the same. The AUC of troponin
T was 0.91 (95% CI 0.87–0.96) in this subgroup, which was slightly
better compared with the overall cohort. All other findings of the
ROC analyses stayed similar (Table 4). Due to the somewhat
higher sensitivity of troponin T in the subgroup without
ST-elevation AMI, sFlt-1 was not found to add significant infor-
mation in patient with troponin T ≤0.01 mg/L and hsTnT
≤0.011 mg/L in our CART model (data not shown).
Figure 3 Receiver operating characteristic curves for the diagnosis of acute myocardial infarction. (A) Performance of high-sensitive troponin
T, troponin T, sFlt-1, and placental growth factor. (B) Performance of troponin T compared with the combination of markers.
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Table 3 Multivariate Cox regression analysis for
mortality during follow-up
HR 95% CI P-value
Soluble fms-like tyrosine kinase-1
.84 ng/L
2.13 1.05–4.31 0.03
Placental growth factor .20 ng/L 1.95 0.64–5.92 0.24
Age (years) 1.08 1.05–1.12 ,0.001
Arterial hypertension 0.51 0.22–1.18 0.11
Diabetes mellitus 1.25 0.58–2.68 0.57
Known coronary artery disease 1.88 0.69–5.13 0.22
Previous myocardial infarction 0.96 0.37–2.52 0.93
Known peripheral artery disease 1.79 0.74–4.31 0.20
Previous stroke 2.17 0.98–4.82 0.06
Impaired renal functiona 1.45 0.71–2.96 0.31
Beta-blocker 1.87 0.93–3.77 0.08
ST-segment elevation 5.91 2.56–13.65 ,0.001
ST-segment depression 2.04 0.90–4.61 0.09
aImpaired renal function defined as glomerular filtration rate ,60 mL/min
(calculated using the MDRD formula).
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Discussion
This study has demonstrated for the first time the prognostic impact
of sFlt-1 in patients with suspected AMI. Furthermore, we could
present the first evidence for the potential impact of sFlt-1 and
PlGF on decision making in patients with suspected AMI. We
present in this manuscript three major findings: first, both markers
provide important prognostic information that is independent from
that of established blood markers (troponin T and NT-proBNP) in
patients presenting with symptoms suggestive for AMI. Soluble
fms-like tyrosine kinase-1, but not PlGF, shows independent prognos-
tic information also after entering all baseline characteristics in our
model. Second, sFlt-1 demonstrates a significant improvement of
diagnostic accuracy in combination with troponin compared with tro-
ponin alone. This leads to a negative predictive value for the diagnosis
of AMI of 98% with a single blood sample drawn at presentation in the
ED that rises to 99% when used together with ECG results available
at this point of time. Third, even when used together with a novel
hsTnT assay, sFlt-1 but not PlGF provides independent prognostic
information. However, due to the excellent sensitivity of hsTnT,
sFlt-1 and PlGF can only add very limited diagnostic information for
identification of patients with AMI, and in the subgroup of patients
without ST-segment elevation AMI sFlt-1 does not further improve
diagnosis of AMI.
It is important to note that, compared with many other trials
investigating biomarkers in patients with suspected AMI, blood
samples were drawn at the earliest point of time which was
already at time of presentation to hospital, and not some time
thereafter. This allows not only a direct transfer of our findings
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Table 4 Diagnostic performance of different assays and combinations at presentation
Sensitivity Specificity Negative
predictive value
Positive
predictive value
Per cent (95% confidence interval)
Entire study population (n5 763)
sFlt-1, 104 ng/L 42 (33–51) 85 (81–87) 87 (84–90) 36 (30–44)
PlGF, 22 ng/L 38 (27–44) 73 (69–77) 81 (84–87) 16 (11–18)
Roche troponin T fourth generation
Troponin T, 0.010 mg/L 83 (75–88) 94 (91–95) 96 (94–98) 73 (65–80)
+ sFlt-1, 104 ng/L 93 (87–97) 81 (77–84) 98 (97–99) 50 (44–57)
+ PlGF, 22 ng/L 89 (83–94) 70 (66–74) 96 (95–98) 38 (33–44)
Roche high-sensitive troponin T
hs Troponin T, 0.011 mg/L 98 (93–99) 72 (68–76) 99 (98–100) 42 (37–48)
+ sFlt-1, 104 ng/L 98 (94–100) 65 (60–68) 100 (98–100) 36 (31–42)
+ PlGF, 22 ng/L 98 (93–99) 58 (54–62) 99 (97–100) 33 (28–38)
Study population without patients with ST-elevation myocardial infarction (n5 724)
sFlt-1, 104 ng/L 40 (30–50) 84 (81–87) 90 (88–93) 27 (20–36)
PlGF, 22 ng/L 30 (21–41) 73 (69–76) 88 (84–90) 14 (10–20)
Roche troponin T fourth generation
Troponin T, 0.010 mg/L 86 (77–92) 94 (91–95) 98 (96–99) 66 (57–74)
+ sFlt-1, 104 ng/L 92 (85–96) 81 (77–84) 99 (97–99) 41 (35–48)
+ PlGF, 22 ng/L 91 (83–96) 70 (66–74) 98 (96–99) 31 (26–37)
Roche high-sensitive troponin T
hs Troponin T, 0.011 mg/L 97 (90–99) 72 (68–76) 99 (98–100) 34 (28–40)
+ sFlt-1, 104 ng/L 98 (91–100) 64 (60–68) 99 (98–100) 29 (24–34)
+ PlGF, 22 ng/L 97 (90–99) 58 (54–62) 99 (97–100) 25 (21–30)
Figure 4 Area under the receiver operating characteristic
curves for the diagnosis of acute myocardial infarction according
to time since onset of chest pain.
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to clinical practice but also makes the implementation of our
results at an early stage of clinical evaluation possible.
Our findings regarding the prognostic information of PlGF are in
line with a substudy from the CAPTURE (c7E3 Fab Anti-Platelet
Therapy in Unstable Refractory Angina) trial, which has demon-
strated that PlGF is an independent predictor for adverse
outcome (death and non-fatal AMI) in patients with suspected
AMI.13 This study also demonstrated that PlGF can extend the
Figure 5 Classification and regression trees analyses for the diagnosis of acute myocardial infarction (A) Only biomarkers at presentation. (B)
Including all variables available at presentation. Proportion of myocardial infarction displayed in black. Size of pie chart denotes the number of
patients in this subgroup.
Figure 6 Classification and regression trees analyses for the diagnosis of acute myocardial infarction using a high-sensitive troponin T assay.
(A) Only biomarkers at presentation. (B) Including all variables available at presentation. Proportion of myocardial infarction displayed in black.
Size of pie chart denotes the number of patients in this subgroup.
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prognostic information derived from the traditional markers,
namely C-reactive protein and soluble CD40-ligand. However, in
our study, only sFlt-1 but not PlGF demonstrated prognostic infor-
mation independent from baseline characteristics or hsTnT.
The findings for sFlt-1 and also for PlGF in our study together
with the diagnostic impact of sFlt-1 when used together with the
contemporary troponin T assay might be explained by the compre-
hensive involvement of both biomarkers in the development and
progression of atherosclerotic disease. This is unique and unlike
most biomarkers which are only involved in single processes
such as inflammatory response, platelet activation, or cell necrosis.
Furthermore, investigations in other diseases or syndromes such as
sepsis,21 acute lung injury,22 neoplasms,23 and preeclampsia24
demonstrated a wide involvement of angiogenic and associated
markers in many conditions with inflammatory processes and/or
hypoxaemia. Animal studies provided first evidence that thera-
peutic inhibition of angiogenic pathways might be beneficial in
some of these conditions.22,23 In human medicine, such therapies
might be beneficial in patients with cardiovascular diseases since
they have elevated levels of such markers.25 Placental growth
factor and sFlt-1 also show a significant increase in blood levels
in patients with AMI undergoing thrombolysis.11,14 The results of
our study extend the previous findings as they transfer the knowl-
edge achieved from basic and observational research to potential
important clinical implications. However, despite the findings of
our study, biomarkers should be used for risk stratification and
diagnosis only in conjunction with a detailed clinical assessment
that can only be made by a skilled clinician taking all available par-
ameters into consideration and not by biomarker testing alone.
Several limitations merit consideration. First, levels of new bio-
markers were not determined immediately, but after samples
were frozen at 2808 for up to 2 years before being analysed
in a batch without ever being thawed. It could be hypothesised
that immediate measurement of biomarkers might have resulted
in an even higher diagnostic accuracy. Second, blood cells contain
certain proteins (e.g. PlGF) that might be released during sample
preparation and might have biased our biomarker assessment.
Third, the used assay detects bound and unbound sFlt-1. Since
vascular endothelial growth factor isoforms26 and PlGF bind to
sFlt-1, a confounding bias affecting the results of sFlt-1 cannot
be excluded. Fourth, since this is a prospective observational
study, we cannot quantify exactly the clinical benefit associated
with the increase in early diagnostic and prognostic accuracy.
Interventional studies are warranted to gain this important
information.
In summary, sFlt-1 and PlGF can provide important prognos-
tic information that is independent from that of troponin T
and NT-proBNP, but only for sFlt-1, also independent from
hsTnT. Soluble fms-like tyrosine kinase-1 demonstrated a
significant improvement of diagnostic accuracy when used
together with a contemporary troponin assay, leading to a
negative predictive value for the diagnosis of AMI of 98%
with a single blood sample drawn at presentation to the ED.
However, due to the excellent sensitivity of hsTnT, sFlt-1,
and PlGF will only add limited diagnostic information for
identification of patients with AMI after the introduction of
this novel assay.
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